Generic DPI device developer Merxin has announced that its MRX003 capsule based dry powder inhaler has received CE marking certification. The inhaler, which was launched in May 2017, is designed for generic tiotropium products submitted for approval under the 505(j) pathway.
Merxin Co-Founder and Director Philippe Rogueda said in a LinkedIn post, “Merxin is committed to excellence and quality: this CE marking seals another milestone in the development of Merxin and demonstrates the readiness of our production facilities.”
